Clinical Trial Update: Efficacy and Safety of RMC-035 in Subjects at High Risk for Acute Kidney Injury Following Open-Chest Cardiac Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of RMC-035 in subjects at high risk for acute kidney injury after open-chest cardiac surgery was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• RMC-035

Snippet

Sponsor: Guard Therapeutics AB | Conditions: Acute Kidney Injury | Phase 2 | Status: TERMINATED | Results posted: 2024-05-16